XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
At The Market Offering
Common Stock
Common Stock
At The Market Offering
Additional Paid-in Capital
Additional Paid-in Capital
At The Market Offering
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance at Dec. 31, 2022 $ 499,315   $ 19   $ 1,558,459   $ (4,327) $ (1,054,836)
Beginning balance (in shares) at Dec. 31, 2022     191,022          
Fees incurred related to common stock financings/issuance of common stock from at the market offering (200)       (200)      
Vesting of restricted stock (in shares)     154          
Exercise of stock options 331       331      
Exercise of stock options (in shares)     233          
Stock-based compensation expense 8,751       8,751      
Unrealized gain (loss) on marketable securities, net 2,188           2,188  
Net income (loss) (82,123)             (82,123)
Ending balance at Mar. 31, 2023 428,262   $ 19   1,567,341   (2,139) (1,136,959)
Ending balance (in shares) at Mar. 31, 2023     191,409          
Beginning balance at Dec. 31, 2022 499,315   $ 19   1,558,459   (4,327) (1,054,836)
Beginning balance (in shares) at Dec. 31, 2022     191,022          
Net income (loss) (196,122)              
Ending balance at Jun. 30, 2023 355,029   $ 20   1,606,832   (865) (1,250,958)
Ending balance (in shares) at Jun. 30, 2023     196,880          
Beginning balance at Mar. 31, 2023 428,262   $ 19   1,567,341   (2,139) (1,136,959)
Beginning balance (in shares) at Mar. 31, 2023     191,409          
Issuance of common stock, net of offering costs (in shares)       4,586        
Issuance of common stock, net of offering costs   $ 27,248   $ 1   $ 27,247    
Fees incurred related to common stock financings/issuance of common stock from at the market offering   (985)            
Vesting of restricted stock (in shares)     119          
Exercise of stock options 691       691      
Exercise of stock options (in shares)     357          
Issuance of common stock related to employee stock purchase plan 1,705       1,705      
Issuance of common stock related to employee stock purchase plan (in shares)     409          
Stock-based compensation expense 9,848       9,848      
Unrealized gain (loss) on marketable securities, net 1,274           1,274  
Net income (loss) (113,999)             (113,999)
Ending balance at Jun. 30, 2023 355,029   $ 20   1,606,832   (865) (1,250,958)
Ending balance (in shares) at Jun. 30, 2023     196,880          
Beginning balance at Dec. 31, 2023 $ 287,506   $ 20   1,625,637   (60) (1,338,091)
Beginning balance (in shares) at Dec. 31, 2023 197,857   197,857          
Issuance of common stock, net of offering costs (in shares)     21,773 150        
Issuance of common stock, net of offering costs $ 180,008 1,037 $ 2   180,006 $ 1,037    
Fees incurred related to common stock financings/issuance of common stock from at the market offering   $ (113)            
Vesting of restricted stock (in shares)     386          
Exercise of stock options 4,929       4,929      
Exercise of stock options (in shares)     1,120          
Stock-based compensation expense 9,092       9,092      
Unrealized gain (loss) on marketable securities, net 45           45  
Net income (loss) (107,475)             (107,475)
Ending balance at Mar. 31, 2024 375,142   $ 22   1,820,701   (15) (1,445,566)
Ending balance (in shares) at Mar. 31, 2024     221,286          
Beginning balance at Dec. 31, 2023 $ 287,506   $ 20   1,625,637   (60) (1,338,091)
Beginning balance (in shares) at Dec. 31, 2023 197,857   197,857          
Exercise of stock options (in shares) 1,662              
Net income (loss) $ (157,766)              
Ending balance at Jun. 30, 2024 $ 339,649   $ 22   1,835,503   (19) (1,495,857)
Ending balance (in shares) at Jun. 30, 2024 222,209   222,209          
Beginning balance at Mar. 31, 2024 $ 375,142   $ 22   1,820,701   (15) (1,445,566)
Beginning balance (in shares) at Mar. 31, 2024     221,286          
Fees incurred related to common stock financings/issuance of common stock from at the market offering (16)       (16)      
Vesting of restricted stock (in shares)     52          
Exercise of stock options 2,361       2,361      
Exercise of stock options (in shares)     548          
Issuance of common stock related to employee stock purchase plan 1,077       1,077      
Issuance of common stock related to employee stock purchase plan (in shares)     323          
Stock-based compensation expense 11,380       11,380      
Unrealized gain (loss) on marketable securities, net (4)           (4)  
Net income (loss) (50,291)             (50,291)
Ending balance at Jun. 30, 2024 $ 339,649   $ 22   $ 1,835,503   $ (19) $ (1,495,857)
Ending balance (in shares) at Jun. 30, 2024 222,209   222,209